LIXTE Biotechnology Holdings pivots to AI energy infrastructure, appoints Stuart Porter of Denham Capital to board. The company seeks partner for its cancer drugLIXTE Biotechnology Holdings pivots to AI energy infrastructure, appoints Stuart Porter of Denham Capital to board. The company seeks partner for its cancer drug

LIXTE Biotechnology Transforms into AI Energy Infrastructure Company, Adds Denham Capital Founder to Board

2026/06/01 22:05
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced a strategic transformation into an AI energy infrastructure equipment and services platform, targeting the growing power demands of artificial intelligence and hyperscale data centers. As part of this shift, Stuart D. Porter, founder, managing partner, CEO and chief investment officer of Denham Capital Management LP, has joined the company’s board of directors, according to a press release.

The company’s new strategy will focus on power equipment and service solutions for AI data-center campuses, distributed power systems and advanced generation technologies. LIXTE also stated it is seeking a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations, which are centered on cancer treatments.

This pivot comes as the energy demands of AI and data centers are expected to surge, creating opportunities for infrastructure providers. By bringing in Porter, whose firm Denham Capital has deep experience in energy and infrastructure investments, LIXTE gains expertise in scaling energy-focused businesses.

LIXTE’s legacy operations include its lead compound LB-100, a first-in-class PP2A inhibitor that has shown promise in enhancing chemotherapies and immunotherapies. The company also owns Liora Technologies Europe Ltd., which is developing the LiGHT System for proton therapy. However, the company is now seeking a partner to advance these assets while it redirects its corporate focus.

The announcement highlights a trend of biotechnology companies pivoting to high-growth sectors like AI infrastructure, leveraging their public listing and capital to enter new markets. LIXTE’s move could provide a pathway to monetize its drug development assets while capitalizing on the AI boom.

For more details, the full press release is available at https://ibn.fm/MVXfg. Additional information about LIXTE can be found at www.lixte.com, and about Liora Technologies at www.lioratechnologies.com.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is LIXTE Biotechnology Transforms into AI Energy Infrastructure Company, Adds Denham Capital Founder to Board.

The post LIXTE Biotechnology Transforms into AI Energy Infrastructure Company, Adds Denham Capital Founder to Board appeared first on citybuzz.

Market Opportunity
Gensyn Logo
Gensyn Price(AI)
$0.03298
$0.03298$0.03298
+2.58%
USD
Gensyn (AI) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage